Latrunculin B
(Synonyms: 红海海绵素 B) 目录号 : GC17006Inhibitor of actin polymerization
Cas No.:76343-94-7
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >96.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
The latrunculins are commonly used to experimentally disrupt the actin cytoskeleton of cells. Latrunculin B causes concentration-dependent changes in cell shape and actin organization. It sequesters G-actin and prevents F-actin assembly. It binds monomeric actin with 1:1 stoichiometry and can be used to block actin polymerization both in vitro and in cells (Kd = 60 nM).[1] The short-term effects of latrunculin B are comparable to those of latrunculin A, although latrunculin B is slightly less potent.[2] However, latrunculin B is gradually inactivated by serum so that induced changes are transient in the continued presence of the compound. For this reason, latrunculin B may have fewer unwanted effects than latrunculin A and may be preferred for short-term studies.
Reference:
[1]. Wakatsuki, T., Schwab, B., Thompson, N.C., et al. Effects of cytochalasin D and latrunculin B on mechanical properties of cells. Journal of Cell Science 114, 1025-1036 (2000).
[2]. Spector, I., Schochet, N.R., Blasberger, D., et al. Latrunculins-novel marine macrolides that disrupt microfilament organization and affect cell growth: I. comparison with cytochalasin D. Cell Motility and the Cytoskeleton 13, 127-144 (1989).
Cas No. | 76343-94-7 | SDF | |
别名 | 红海海绵素 B | ||
化学名 | 4R-[(1R,4Z,8Z,10S,13R,15R)-15-hydroxy-5,10-dimethyl-3-oxo-2,14-dioxabicyclo[11.3.1]heptadeca-4,8-dien-15-yl]-2-thiazolidinone | ||
Canonical SMILES | C/C(CC/C=C\[C@@H](C)CC[C@@H]1C[C@@H]2C[C@@]([C@H]3N([H])C(SC3)=O)(O)O1)=C/C(O2)=O | ||
分子式 | C20H29NO5S | 分子量 | 395.5 |
溶解度 | ≤25mg/ml in DMSO; 25 mg/ml in Ethanol | 储存条件 | Store at -20°C,protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.5284 mL | 12.6422 mL | 25.2845 mL |
5 mM | 0.5057 mL | 2.5284 mL | 5.0569 mL |
10 mM | 0.2528 mL | 1.2642 mL | 2.5284 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。